RxDoctor Payments Data

Roy Lin, MD

Clinical Cardiac Electrophysiology · Wenatchee, WANPI 1043582315

Payments from drug & device makers

What this record shows

This record is dominated by travel and lodging: $4,297 of the $6,189 with a category attached, or 69.4%. 12 manufacturers reported payments, led by Biotronik Inc. at 32.8% of the total. Reporting peaked in 2019 at $4,235 and has fallen 97.3% since, to $114 in 2025. That places this record below the midpoint for clinical cardiac electrophysiology clinicians in WA, where the typical reported total is $7,912.

$6,189in general payments, 2019–2025

Across 54 payments — averaging $114.61 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Biotronik Inc.$2K
  • Abbott$2K
  • Medtronic$2K
  • Boston Scientific$351
  • Sanofi$117
  • ZOLL Services LLC (a/k/a ZOLL Lifecor Corp)$38
  • plus $127 from 6 others

What the payments were for

  • Travel & lodging$4,29769%
  • Food & beverage$1,89231%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$6,189 in reported general payments places this provider in the 45th percentile of 68 clinical cardiac electrophysiology providers in Washington.

See all clinical cardiac electrophysiology providers in Washington

Medicare billing

Part B allowed, 2024
$253,148
Medicare patients
1,367
Services billed
3,085

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban18$23,354
Flecainide Acetate50$2,521
Amiodarone Hcl39$1,678
Diltiazem 24hr Er (Cd)Diltiazem Hcl16$1,397
Colchicine30$1,144
Metoprolol Succinate33$1,056
SotalolSotalol Hcl28$262
Carvedilol12$243
Furosemide21$120
Spironolactone23$120
Lisinopril12$113
Metoprolol Tartrate11$29

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$26$23,35418 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 45th percentile of 68 clinical cardiac electrophysiology providers in Washington.

Other clinical cardiac electrophysiology in Wenatchee

See the full list for Washington

Where these figures come from

Is this you, or does something look wrong? →